Prognostic value of cardiopulmonary biomarkers in relation to the development of bronchopulmonary dysplasia and pulmonary hypertension in premature infants

• Conditions: Neonatal cardiac failure; P29.0; Bronchopulmonary dysplasia originating in the perinatal period; P27.1; Persistent fetal circulation; P29.3

• Registration Number: DRKS00033219
• Lead Sponsor: niversitätsklinikum Bonn

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-12-13
• Study Completion: 2024-07-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

1) Birth weight <1500g

Exclusion Criteria

=30/1 weeks of GA, early death (<7 days of life), primary palliative care, congenital heart defects (CHD) requiring surgical repair. A patent ductus arteriosus (PDA), an atrial septal defect (ASD, <5mm) and a muscular ventricular septal defect (VSD, <2mm) were not classified as relevant CHD.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Combined primary endpoint: diagnosis of bronchopulmonary dysplasia (BPD) and/or death (whichever occurs first)

Secondary Outcome Measures

Name	Time	Method
1) The development of pulmonary hypertension<br>2) The development of right ventricular or left ventricular cardiac dysfunction<br>3) Duration of supplemental oxygen administration<br>4) Duration of mechanical ventilation<br>5) Duration of hospital stay